415 related articles for article (PubMed ID: 12829905)
1. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study.
Husain S; Tollemar J; Dominguez EA; Baumgarten K; Humar A; Paterson DL; Wagener MM; Kusne S; Singh N
Transplantation; 2003 Jun; 75(12):2023-9. PubMed ID: 12829905
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
3. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.
Parkins MD; Sabuda DM; Elsayed S; Laupland KB
J Antimicrob Chemother; 2007 Sep; 60(3):613-8. PubMed ID: 17576697
[TBL] [Abstract][Full Text] [Related]
4. Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation.
Shi SH; Lu AW; Shen Y; Jia CK; Wang WL; Xie HY; Zhang M; Liang TB; Zheng SS
Chin Med J (Engl); 2008 Apr; 121(7):625-30. PubMed ID: 18466683
[TBL] [Abstract][Full Text] [Related]
5. Trends in invasive disease due to Candida species following heart and lung transplantation.
Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
[TBL] [Abstract][Full Text] [Related]
6. Potential risk factors for infection with Candida spp. in critically ill patients.
Peres-Bota D; Rodriguez-Villalobos H; Dimopoulos G; Melot C; Vincent JL
Clin Microbiol Infect; 2004 Jun; 10(6):550-5. PubMed ID: 15191384
[TBL] [Abstract][Full Text] [Related]
7. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
8. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
9. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.
Safdar A; Hanna HA; Boktour M; Kontoyiannis DP; Hachem R; Lichtiger B; Freireich EJ; Raad II
Cancer; 2004 Dec; 101(12):2859-65. PubMed ID: 15529309
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial.
Magill SS; Swoboda SM; Shields CE; Colantuoni EA; Fothergill AW; Merz WG; Lipsett PA; Hendrix CW
Ann Surg; 2009 Apr; 249(4):657-65. PubMed ID: 19300221
[TBL] [Abstract][Full Text] [Related]
11. [Epidemiological features of Candida infections detected in intensive care units and risk factors affecting mortality].
Acar A; Oncül O; Küçükardali Y; Ozyurt M; Haznedaroğlu T; Cavuşlu S
Mikrobiyol Bul; 2008 Jul; 42(3):451-61. PubMed ID: 18822889
[TBL] [Abstract][Full Text] [Related]
12. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome.
Dimopoulos G; Ntziora F; Rachiotis G; Armaganidis A; Falagas ME
Anesth Analg; 2008 Feb; 106(2):523-9, table of contents. PubMed ID: 18227310
[TBL] [Abstract][Full Text] [Related]
13. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
[TBL] [Abstract][Full Text] [Related]
14. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
16. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality.
Safdar N; Said A; Lucey MR; Knechtle SJ; D'Alessandro A; Musat A; Pirsch J; McDermott J; Kalayoglu M; Maki DG
Clin Infect Dis; 2004 Aug; 39(4):517-25. PubMed ID: 15356815
[TBL] [Abstract][Full Text] [Related]
17. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
[TBL] [Abstract][Full Text] [Related]
19. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.
Davis SL; Vazquez JA; McKinnon PS
Ann Pharmacother; 2007 Apr; 41(4):568-73. PubMed ID: 17374623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
